Dapagliflozin in PRESERVED Ejection Fraction Heart Failure

PHASE4CompletedINTERVENTIONAL
Enrollment

324

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

August 13, 2021

Study Completion Date

August 13, 2021

Conditions
Chronic Heart Failure With Preserved Systolic Function
Interventions
DRUG

Dapagliflozin 10Mg Oral Tablet

Dapagliflozin 10Mg Oral Tablet

DRUG

Dapagliflozin matching placebo

Dapagliflozin matching placebo

Trial Locations (26)

10032

Columbia University, New York

11576

St. Francis Hospital, New York

15212

Allegheny Health Network Research Institute, Pittsburgh

21205

Johns Hopkins University, Baltimore

23501

Eastern Virginia Medical School, Norfolk

27157

Wake Forest University, Winston-Salem

28562

Eastern Nephrology Associates, New Bern

30303

Emory University, Atlanta

32256

First Coast Cardiovascular Institute, Jacksonville

33952

Charlotte Heart Group Research Center, Port Charlotte

36532

Heart Group of the Eastern Shore, Fairhope

37232

Vanderbilt University Medical Center, Nashville

46260

St. Vincent Cardiovascular Research Institute, Indianapolis

55905

Mayo Clinic, Rochester

60201

NorthShore University HealthSystem Research Insititute, Evanston

60208

Northwestern University, Evanston

60429

Chicago Medical Research, Hazel Crest

61606

OSF HealthCare Cardiovascular Institute, Peoria

63110

Washington University, St Louis

64111

Saint Luke's Mid America Heart Institute, Kansas City

66606

Cotton O'Neil Clinical Research Center, Topeka

75204

Baylor Scott and White Research Institute, Dallas

84112

University of Utah, Salt Lake City

90032

University of Southern California, Los Angeles

97239

Oregon Health and Science University, Portland

02114

Massachusetts Hospital, Boston

All Listed Sponsors
lead

Saint Luke's Health System

OTHER

NCT03030235 - Dapagliflozin in PRESERVED Ejection Fraction Heart Failure | Biotech Hunter | Biotech Hunter